Figure 2.

A  Safety/PK component

Screened  (n = 20)

Randomized  (n = 16)

Maraviroc 150 mg BID  (n = 8)

Discontinued  (n = 1)
   Not related to study drug  (n = 1)
   AE  (n = 1)

Completed  (n = 7)
   Analyzed for safety  (n = 8)

Maraviroc 300 mg BID  (n = 8)

Discontinued  (n = 0)

Completed  (n = 8)
   Analyzed for safety  (n = 8)

B  Proof-of-concept component

Screened  (n = 198)

Randomized  (n = 112)

Placebo  (n = 33)

Maraviroc 300 mg BID  (n = 77)

Discontinued  (n = 22)
   Related to study drug  (n = 8)
   AE  (n = 1)
   LOE  (n = 2)
   Other  (n = 5)
   Not related to study drug  (n = 6)
   AE  (n = 3)
   NLW  (n = 3)

Completed  (n = 19)
   Analyzed for efficacy:
   Full analysis  (n = 33)
   Interim analysis  (n = 21)
   Analyzed for safety  (n = 33)

Discontinued because the study was terminated by the sponsor.

AE = adverse event; BID = twice daily; LOE = lack of efficacy; NLW = no longer willing (to participate in study).